Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kisplyx

- PMLiVE

Eisai expands in Europe with new Belgium business

Will coordinate local reimbursement for cancer drug Halaven

- PMLiVE

Breakthrough status for GSK/ Genmab’s Arzerra

Speeds up FDA review for use in chronic lymphocytic leukaemia

- PMLiVE

Eisai launches Halaven in Russia

Expands market reach of its breast cancer drug to cover emerging market

- PMLiVE

FDA panel backs Perjeta in early breast cancer

Unanimous recommendation for use alongside Herceptin

- PMLiVE

Eisai lines-up Fycompa access programme for Germany

But sales suspension for epilepsy drug will continue

- PMLiVE

FDA guidance clears path for Advair generics

Offers simplified process for potential copies of GSK’s asthma and COPD drug

- PMLiVE

Celgene wins US pancreatic cancer indication for Abraxane

Adds to breast cancer and lung cancer indications

- PMLiVE

FDA grants priority review to Takeda’s colitis drug

Accelerates review time for vedolizumab

- PMLiVE

Lundbeck still ‘appalled’ by EC’s €94m anti-competition fine

Will appeal, but doesn't expect a quick decision

- PMLiVE

FDA investigates safety of Novartis’ MS drug

Agency to determine association between Gilenya and rare brain infection

- PMLiVE

FDA turns down Otsuka’s kidney disease candidate

Requests additional information for tolvaptan

Bayer symbol

EU nod for Bayer’s Stivarga as Nexavar gets US priority review

Advances pharma company’s ambitions in cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links